In a statement, the company said the therapy was authorized for the treatment of Quote mild to Moderate Cove in 19 in patients aged 12 or older who are at high risk of progressing to severe Cove in 19 and or hospitalization.
在一份聲明中,該公司表示,該療法被授權用於治療報價輕度至中度凹陷的19歲以上的12歲或以上的患者,他們有很高的風險發展到嚴重的凹陷和或住院治療。